Roflumilast foam 0.3%, a non-steroidal PDE4 inhibitor, has shown significant promise for treating psoriasis in adults and adolescents aged 12 and older. Presented at the Fall Clinical Dermatology Conference, data from the ARRECTOR phase 3 study revealed that over 50% of patients reported minimal or no itch after eight weeks of treatment. This once-daily topical medication, which is aesthetically pleasing and not greasy, provides an easy and effective option for patients, offering both convenience and comfort compared to traditional treatments. Roflumilast foam is especially useful for patients struggling with psoriasis-related itch, a common and distressing symptom.

The ARRECTOR study also highlighted the positive patient-reported outcomes, with patients experiencing substantial reductions in itch, particularly on the scalp, where scratching can worsen the condition. Additionally, the treatment was associated with fewer adverse events and high local tolerability, with low rates of drug discontinuation due to side effects. This phase 3 data supports the effectiveness and safety of roflumilast foam 0.3% in treating psoriasis, marking it as a promising new option for managing this chronic skin condition.

Reference: Smith T. New Findings on Psoriasis Outcomes for Roflumilast Foam 0.3%, with Melinda Gooderham, MD. HCPLive. Published November 1, 2024. Accessed March 22, 2025. https://www.hcplive.com/view/new-findings-on-psoriasis-outcomes-roflumilast-foam-0-3-melinda-gooderham-md